Alamar Biosciences director restructures stock options

Alamar Biosciences director Frank Witney reported internal option restructurings related to the company’s share reclassification.

Rhea-AI Filing Summary

Alamar Biosciences director Frank Witney reported internal option restructurings related to the company’s share reclassification. On April 20, 2026, six Form 4 transactions with code J moved stock options between underlying Class B Common Stock and Common Stock at no transaction price.

The filing shows options for 124,069 shares at an exercise price of $7.60 expiring on January 14, 2036, 33,085 shares at $3.10 expiring on April 15, 2035, and 49,627 shares at $0.59 expiring on April 20, 2031. A footnote states each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering.

Insider Trade Summary

Other: 413,562 shares

Other 6 txns

Insider Witney Frank

Role Director

Type	Security	Shares	Price	Value
Other	Stock Option (Right to Buy)	49,627	$0.00	$0.00
Other	Stock Option (Right to Buy)	49,627	$0.00	$0.00
Other	Stock Option (Right to Buy)	33,085	$0.00	$0.00
Other	Stock Option (Right to Buy)	33,085	$0.00	$0.00
Other	Stock Option (Right to Buy)	124,069	$0.00	$0.00
Other	Stock Option (Right to Buy)	124,069	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 206,781 contracts (Direct)

Footnotes (4)

1. F1. Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock.
2. F2. Fully vested.
3. F3. The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date.
4. F4. Twenty-five percent of the shares subject to the option vest on January 15, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date.

Key Figures

Total restructuring shares: 413,562 shares Option grant 1 size: 124,069 shares Option grant 1 strike: $7.60 per share +5 more

8 metrics

Total restructuring shares 413,562 shares J-code restructuring transactions summary

Option grant 1 size 124,069 shares Stock option at $7.60 exercise price, expiring January 14, 2036

Option grant 1 strike $7.60 per share Exercise price for 124,069-share option grant

Option grant 2 size 33,085 shares Stock option at $3.10 exercise price, expiring April 15, 2035

Option grant 2 strike $3.10 per share Exercise price for 33,085-share option grant

Option grant 3 size 49,627 shares Stock option at $0.59 exercise price, expiring April 20, 2031

Option grant 3 strike $0.59 per share Exercise price for 49,627-share option grant

Transaction date April 20, 2026 All six J-code derivative transactions

Key Terms

Stock Option (Right to Buy), Class B Common Stock, initial public offering, reclassified, +2 more

6 terms

Stock Option (Right to Buy) financial

""security_title": "Stock Option (Right to Buy)""

Class B Common Stock financial

""underlying_security_title": "Class B Common Stock""

A class B common stock is one of multiple types of a company’s ordinary shares that carries specific rights—often different voting power or dividend priority—compared with other classes. For investors it matters because those differences affect how much influence you have over company decisions, the income you might receive, and how freely the shares trade; think of it like owning a car with different keys: some keys let you start the engine and open the trunk, others only unlock the door.

initial public offering financial

"prior to the completion of the initial public offering of the Issuer's Common Stock"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

reclassified financial

"Each share of Class B Common Stock was reclassified into one share of Common Stock"

vest in equal monthly installments financial

"The shares subject to the option vest in equal monthly installments over 48 months"

continuous service financial

"subject to the reporting person's continuous service as of each such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alamar Biosciences (ALMR) director Frank Witney report in this Form 4?

Frank Witney reported six option restructuring transactions coded J on April 20, 2026. These moved stock options between Class B Common Stock and Common Stock with no transaction price, reflecting internal changes tied to the company’s share reclassification before its initial public offering.

How many Alamar Biosciences (ALMR) shares are covered by Frank Witney’s restructured options?

The restructuring involves options over a total of 413,562 shares. This consists of 124,069, 33,085 and 49,627 optioned shares, each mirrored once for Class B Common Stock and once for Common Stock, as shown by the paired J-code transactions in the filing.

What are the exercise prices of Frank Witney’s Alamar Biosciences (ALMR) stock options?

Witney’s options have exercise prices of $7.60, $3.10 and $0.59 per share. Each price applies to a separate option grant, with differing share amounts and expiration dates, providing multiple strike levels for potential future exercises of Alamar Biosciences common stock.

When do Frank Witney’s Alamar Biosciences (ALMR) stock options expire?

The options expire on three different dates: January 14, 2036, April 15, 2035 and April 20, 2031. Each expiration date corresponds to a distinct grant with its own exercise price and share count, defining how long Witney retains the right to buy shares.

What does the Class B Common Stock reclassification mean for Alamar Biosciences (ALMR) options?

A footnote explains that each share of Class B Common Stock was reclassified into one share of Common Stock before the initial public offering. The option records show corresponding positions in both classes, indicating the restructuring aligns option rights with the new single common stock class.

Are Frank Witney’s Alamar Biosciences (ALMR) options vested or subject to future vesting?

One footnote states a grant is fully vested, while others vest over time. For example, some options vest in equal monthly installments over 48 months from January 1, 2025, and another grant vests 25% on January 15, 2027 with monthly vesting thereafter, contingent on continuous service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/20/2026 - 08:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Witney Frank

(Last) (First) (Middle)

C/O ALAMAR BIOSCIENCES, INC.

47071 BAYSIDE PARKWAY

(Street)

FREMONT CALIFORNIA 94538

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alamar Biosciences, Inc. [ ALMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.59	04/20/2026		J(1)			49,627	(2)	04/20/2031	Class B Common Stock	49,627	$0	0	D
Stock Option (Right to Buy)	$0.59	04/20/2026		J(1)		49,627		(2)	04/20/2031	Common Stock	49,627	$0	49,627	D
Stock Option (Right to Buy)	$3.1	04/20/2026		J(1)			33,085	(3)	04/15/2035	Class B Common Stock	33,085	$0	0	D
Stock Option (Right to Buy)	$3.1	04/20/2026		J(1)		33,085		(3)	04/15/2035	Common Stock	33,085	$0	33,085	D
Stock Option (Right to Buy)	$7.6	04/20/2026		J(1)			124,069	(4)	01/14/2036	Class B Common Stock	124,069	$0	0	D
Stock Option (Right to Buy)	$7.6	04/20/2026		J(1)		124,069		(4)	01/14/2036	Common Stock	124,069	$0	124,069	D

Explanation of Responses:

1. Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock.

2. Fully vested.

3. The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2025, subject to the reporting person's continuous service as of each such vesting date.

4. Twenty-five percent of the shares subject to the option vest on January 15, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date.

	/s/ Timothy White, Attorney-in-Fact	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)